{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Tertomotide",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.",
    "fdaUniiCode": "55R7RG342O",
    "identifier": "C62756",
    "preferredName": "Tertomotide",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C1663",
      "C1752"
    ],
    "synonyms": [
      "GV 1001",
      "GV-1001",
      "GV1001",
      "Human Telomerase Reverse Transcriptase (EC 2.7.7.49)-(611-626)-Peptide (Telomerase Catalytic Subunit Fragment)",
      "PrimoVax",
      "TERTOMOTIDE",
      "Tertomotide"
    ]
  }
}